Becton, Dickinson and Company Accounts Receivable decreased by 12.1% to $2.21B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.2%, from $3.03B to $2.21B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows relatively stable performance with a -0.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to sales may signal collection issues, while a decrease suggests efficient cash conversion.
This represents the balance of money owed to the company by customers for goods or services delivered, adjusted for an a...
Standard metric for all B2B companies; peers in medical devices typically track Days Sales Outstanding (DSO) to benchmark this.
accounts_receivable_net| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.08B | $2.35B | $2.18B | $2.30B | $2.22B | $2.19B | $2.28B | $2.41B | $2.41B | $2.53B | $2.27B | $2.56B | $2.60B | $3.03B | $2.64B | $3.03B | $2.94B | $2.40B | $2.51B | $2.21B |
| QoQ Change | — | +13.1% | -7.4% | +5.8% | -3.7% | -1.2% | +4.2% | +5.7% | +0.0% | +5.0% | -10.5% | +12.9% | +1.4% | +16.8% | -13.0% | +14.8% | -2.8% | -18.6% | +4.7% | -12.1% |
| YoY Change | — | — | — | — | +6.7% | -6.8% | +4.8% | +4.8% | +8.8% | +15.7% | -0.7% | +6.1% | +7.5% | +19.7% | +16.4% | +18.4% | +13.4% | -21.0% | -4.9% | -27.2% |